GLP-1 Without Insurance: What You’ll Actually Pay

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates. This article is informational and is not medical advice; talk to a licensed clinician before starting, stopping or switching any medication.

If you have looked into a GLP-1 medication for weight loss or type 2 diabetes, you have probably already had the sticker-shock moment: a list price north of $1,000 a month, and an insurance plan that either does not cover the drug at all or buries it behind a prior authorization. The good news for 2026 is that the gap between the list price and what an out-of-pocket patient can actually pay has never been wider. The bad news is that the system is now genuinely confusing — there are list prices, manufacturer self-pay prices, a brand-new federal platform, retail cash discounts, a Medicare program that starts mid-year, and compounded options that cost a fraction of everything else. This guide breaks down every route, with real 2026 numbers, so you can see exactly what your cheapest legitimate option is.

List Price: What GLP-1s Cost at the Pharmacy Counter

The “list price” (also called the wholesale acquisition cost) is the manufacturer’s published price before any insurance, coupon or discount. Almost nobody actually pays this — but it is the number your pharmacy quotes when a drug is not covered, so it is the worst-case anchor. As of May 2026, the monthly list prices for the major GLP-1 medications are roughly:

A few things worth knowing before you read those numbers as final. Ozempic and Mounjaro are approved primarily for type 2 diabetes, so commercial and Medicare plans cover them far more often than the weight-management brands. Wegovy and Zepbound are the obesity-indicated brands, and coverage for them is hit or miss unless you also have a qualifying condition. And the entire table is in motion: in February 2026, Novo Nordisk announced it will cut the list price of its three semaglutide products — Wegovy, Ozempic and Rybelsus — to $675 a month, effective January 1, 2027. Novo has said that change applies to the list price and will not lower its direct-to-consumer self-pay prices, but list price is still becoming less relevant every quarter, because almost every patient now has a cheaper door to walk through.

Foundayo deserves a separate note. It is the newest entry — Eli Lilly’s once-daily oral GLP-1 (orforglipron), FDA-approved on April 1, 2026 for chronic weight management. Because it launched into the post-TrumpRx pricing environment, it never really had a four-figure list price for self-pay patients; Lilly priced it directly for cash buyers from day one. We cover its numbers in the self-pay section below.

TrumpRx: The 2026 Pricing Reset

The single biggest change for out-of-pocket GLP-1 buyers in 2026 is TrumpRx (TrumpRx.gov), the federal direct-to-consumer platform that launched on February 5, 2026. It is important to understand what it is and is not: TrumpRx does not sell or ship medication itself. It is a government-run portal that routes you to manufacturers’ own direct-to-consumer pages at negotiated “most-favored-nation” cash prices, and links to coupons you can take to a pharmacy.

According to the White House launch fact sheet, the platform brings the following cash prices for self-pay patients, varying by dose:

• Ozempic and injectable Wegovy: down from list prices of about $1,028 and $1,349 to an average of roughly $350 a month, and as low as $199 for some doses.
• Wegovy oral tablet: as low as $149 a month, depending on dose.
• Zepbound: down from about $1,088 to an average of roughly $346, and as low as $299 for the starting dose.

The administration has said the average injectable price is expected to drift down toward $245 over the next two years. There are caveats worth keeping in mind. Pricing varies by dosage strength, so the headline “as low as” figures usually apply to starter doses, not the maintenance doses most patients end up on. And because TrumpRx simply hands you off to the manufacturer’s own self-pay program, the practical prices you see are essentially the NovoCare and LillyDirect numbers described in the next section — TrumpRx is the front door, not a separate pharmacy.

Manufacturer Self-Pay Programs

Both Novo Nordisk and Eli Lilly now run their own cash-pay channels. These sell FDA-approved brand medication directly to patients who are paying out of pocket, and they are the realistic “brand without insurance” prices for most people in 2026.

Novo Nordisk (NovoCare Pharmacy, ozempic.com, wegovy.com)

• Ozempic injection: an introductory self-pay offer of $199 a month for the first two months (the 0.25 mg and 0.5 mg starter doses). After that, the standard self-pay price is $349 a month for the 0.25 mg, 0.5 mg and 1 mg doses, and $499 a month for the 2 mg dose.
• Wegovy injection: an introductory self-pay price of $199 a month for the first two fills, then $349 a month afterward.
• Wegovy oral tablet: an introductory price of $149 a month, then $299 a month for maintenance doses.

Eli Lilly (LillyDirect)

Lilly sells Zepbound directly to self-pay patients as single-dose vials and KwikPens. The standard LillyDirect self-pay prices are $299 a month for the 2.5 mg dose, $399 for 5 mg, $499 for 7.5 mg, and $699 for the 10 mg, 12.5 mg and 15 mg doses. A separate promotion — the Zepbound Self Pay Journey Program — has reduced the 7.5 mg through 15 mg doses to $449 a month, though promotional pricing carries its own enrollment conditions and can change. If you are quoting your own budget, plan around the standard $299–$699 ladder and treat the $449 promo as a bonus, not a guarantee.

Lilly also sells Foundayo (orforglipron) through LillyDirect: $149 a month for the 0.8 mg starting dose, $199 for the 2.5 mg dose, and $299 for the 5.5 mg, 9 mg, 14.5 mg and 17.2 mg doses. Eligible patients with commercial insurance can pay as little as $25 a month using the Foundayo savings card. Foundayo is also available through GoodRx and a growing number of telehealth providers starting around $149 a month.

One brand that does not have a broad cash-pay vial program is Mounjaro. Because Mounjaro is the type 2 diabetes brand of tirzepatide, Lilly’s self-pay vial program runs under the Zepbound name. Mounjaro patients without coverage are generally left with the full list price or a GoodRx-style discount, which is one reason a tirzepatide patient paying cash usually ends up on Zepbound rather than Mounjaro.

Retail and Pharmacy Cash Discounts

If you would rather pick the medication up at a local pharmacy, a few cash routes can still trim the price:

• Costco / Sesame: Costco members can access Ozempic and Wegovy at a discounted cash price — around $499 a month — through a partnership with Sesame. You generally do not need to be a Costco member to use Sesame directly.
• GoodRx and other coupon cards: free discount coupons can knock a brand’s cash price down somewhat. As an example, a GoodRx coupon recently brought a common Zepbound dose to roughly $995 a month against an average retail cash price near $1,266. That is a real saving, but still far above the manufacturer self-pay channels.

The honest takeaway: in 2026, pharmacy coupon cards are no longer the cheapest route for GLP-1s. The manufacturer self-pay programs and TrumpRx routinely beat them. Coupons are now a backup, useful mainly if you need a specific dose or pharmacy that the direct programs do not serve.

Compounded GLP-1: The Lowest-Cost Route

Compounded semaglutide and tirzepatide are custom-prepared versions of the same active molecule found in the brand drugs, made by a licensed compounding pharmacy rather than by Novo Nordisk or Eli Lilly. They are typically supplied as injectable vials, often combined with an additive such as vitamin B12 or glycine. They are not FDA-approved finished products — the active ingredient is the same, but the compounded preparation itself does not carry FDA approval, and that is an important distinction to understand before choosing this route.

Compounded GLP-1 became widely available between 2022 and 2025 while semaglutide and tirzepatide were on the FDA drug shortage list. The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024, which ended the shortage-based pathway that 503B outsourcing facilities had been using at industrial scale. However, 503A patient-specific compounding — where a state-licensed pharmacy prepares a medication against an individual prescription — remains legal in 2026 and operates independently of shortage status. This is the pathway most reputable telehealth providers now use.

The regulatory picture is still tightening, and you should know about it. On April 30, 2026, the FDA published a proposal to remove semaglutide, tirzepatide and liraglutide from the 503B Bulks List, with a public comment period running through late June 2026. That is a proposal, not a ban, and it targets large-scale 503B bulk compounding — it does not eliminate 503A patient-specific compounding. Still, anyone choosing a compounded route should pick a properly licensed pharmacy, insist on a valid prescription written by a licensed clinician, and have a contingency plan in case their source changes.

On price, compounded semaglutide is the lowest-cost semaglutide route for patients paying out of pocket. Provider pricing varies, but ongoing treatment commonly runs around $300 a month or less, with first-month promotional pricing lower still — often less than the brand manufacturers’ own self-pay programs and less than TrumpRx. For a semaglutide patient who has been denied coverage and is staring at a $16,000-a-year Wegovy list price, the difference is the difference between affordable and impossible.

For a deeper look at compounded GLP-1 — how to vet a compounding pharmacy, and how compounded semaglutide compares with the brand drugs — see our guides to verifying a compounding pharmacy and switching between compounded and brand-name semaglutide.

The Medicare GLP-1 Bridge (Starts July 1, 2026)

For Medicare beneficiaries, a major change arrives mid-year. Medicare has historically been barred from covering medications used for weight loss, which left many older adults paying full price for Wegovy or Zepbound. The Medicare GLP-1 Bridge, a temporary CMS demonstration program, changes that for a limited window.

• Dates: July 1, 2026 through December 31, 2027.
• Cost to you: a flat $50 copayment for each 30-day supply.
• Covered drugs: Wegovy (injection and oral tablet), the Zepbound KwikPen, and Foundayo.
• Eligibility: you must be enrolled in a Medicare Part D plan. From there, a BMI of 35 or higher qualifies on its own, or a BMI of 27 or higher plus a qualifying condition such as heart disease or prediabetes.
• Prior authorization: required — your prescriber must attest that you met the BMI criterion when therapy began.

There is one structural detail that matters for your budget. The Bridge program operates outside the standard Part D benefit, which means the $50 copay does not count toward your Part D deductible or toward the $2,100 annual out-of-pocket cap. Also note that if you are already taking a GLP-1 for type 2 diabetes, sleep apnea or another Medicare-covered use, you keep accessing it through your regular Part D plan at your plan’s cost-sharing — the Bridge is specifically the obesity-indication pathway. After the Bridge ends, a longer-term program called the BALANCE Model is scheduled to take over in 2027, though its Part D component has already faced a delay.

Medicaid and Commercial Insurance Realities

If you have Medicaid, GLP-1 coverage for obesity depends entirely on your state. As of early 2026, only about 13 state Medicaid programs covered GLP-1 drugs specifically for weight loss; coverage for the diabetes indication is much more common. Check your own state’s Medicaid formulary before assuming either way.

With commercial (employer or marketplace) insurance, the pattern is consistent: the diabetes brands — Ozempic, Mounjaro — are covered far more often than the obesity brands — Wegovy, Zepbound. Even when a weight-management GLP-1 is on the formulary, plans frequently require a prior authorization, documentation of a BMI threshold, proof you have tried lifestyle changes, or step therapy through a cheaper drug first. If your plan covers the drug, your copay can be as low as $25 a month with a manufacturer copay card layered on top — which is why it is always worth checking coverage before defaulting to a cash route.

Annual Cost Comparison: Every Route Side by Side

Here is the practical bottom line — roughly what a full year of GLP-1 treatment costs depending on how you pay. Self-pay figures blend introductory and maintenance pricing where programs offer an intro discount.

Read top to bottom, the table tells a clear story. The list price is a worst case almost nobody should accept in 2026. If you have insurance coverage or qualify for the Medicare Bridge, that is virtually always your cheapest route. If you are paying entirely out of pocket, the realistic floor is the cluster around $3,300–$4,200 a year — manufacturer self-pay programs, TrumpRx, the oral option Foundayo, and compounded semaglutide all land in roughly the same range, with compounded semaglutide and Foundayo at the lower edge.

How to Appeal an Insurance Denial

If your plan denied a GLP-1, a denial is not always final. A structured appeal succeeds often enough to be worth the effort:

1. Read the denial letter carefully. It states the exact reason — not on formulary, prior authorization missing, step therapy not completed, or BMI documentation absent. Your appeal has to answer that specific reason.
2. Ask your prescriber for a letter of medical necessity. This should document your BMI, weight-related conditions, prior weight-loss attempts, and why this specific medication is appropriate.
3. Submit the formal internal appeal within your plan’s deadline (often 60–180 days). Include the medical necessity letter and any supporting records.
4. If the internal appeal fails, request an external review. An independent third party re-examines the decision, and in many cases their ruling is binding on the insurer.
5. Explore alternatives in parallel. While the appeal is pending, a manufacturer self-pay program or a compounded route can keep you on therapy rather than forcing a treatment gap.

Frequently Asked Questions

What is the cheapest GLP-1 without insurance in 2026?

For semaglutide specifically, compounded semaglutide from a licensed 503A pharmacy is typically the lowest-cost route, often around $3,400 a year. Foundayo (the oral orforglipron pill) is comparably priced through LillyDirect self-pay. Brand manufacturer self-pay programs and TrumpRx land slightly higher, around $3,900–$4,200 a year. The single cheapest option overall is having the drug covered by insurance or the Medicare Bridge, where you pay only a copay.

Is TrumpRx a pharmacy?

No. TrumpRx.gov is a federal portal that connects you to drug manufacturers’ own direct-to-consumer programs at negotiated cash prices and links to pharmacy coupons. It does not dispense or ship medication itself, so the prices you ultimately pay are the manufacturers’ self-pay prices.

Does Medicare cover Ozempic or Wegovy for weight loss?

Medicare covers GLP-1s prescribed for type 2 diabetes or an approved cardiovascular or sleep-apnea indication. For weight loss alone, coverage was historically prohibited — but the temporary Medicare GLP-1 Bridge program changes that from July 1, 2026 through December 31, 2027, offering eligible Part D beneficiaries Wegovy, Zepbound KwikPen and Foundayo for a $50 monthly copay.

Is compounded semaglutide legal?

Compounded semaglutide prepared by a state-licensed 503A pharmacy against an individual patient prescription remains legal in 2026, independent of the FDA shortage list. The compounded product is not FDA-approved, and the regulatory environment is tightening — the FDA proposed in April 2026 to remove semaglutide from the 503B bulk-compounding list. Use only properly licensed pharmacies and a valid prescription from a licensed clinician.

Why is Wegovy more expensive than Ozempic?

They contain the same active ingredient — semaglutide — but Wegovy is dosed and approved for chronic weight management while Ozempic is approved for type 2 diabetes. Wegovy carries a higher list price, and because it is an obesity-indicated brand it is also less consistently covered by insurance, so out-of-pocket patients feel the gap twice over.

Will GLP-1 prices keep dropping?

The trend points downward. TrumpRx pricing is projected to ease toward roughly $245 a month for injectables over two years, and Novo Nordisk has announced it will cut the list price of its semaglutide products to $675 a month from January 1, 2027. New oral options like Foundayo are also adding price competition. Nothing is guaranteed, but 2026 buyers are negotiating from a far better position than buyers a year ago.

The Bottom Line

The list price of a GLP-1 in 2026 is a number to ignore, not a number to budget around. Start by checking whether your insurance covers the drug, because a covered copay beats every cash route. If you are on Medicare, mark July 1, 2026 — the GLP-1 Bridge could take you to a $50 monthly copay. And if you are paying fully out of pocket, you have a genuine spread of options that all land in the $3,300–$4,200-a-year range: manufacturer self-pay through TrumpRx, the oral pill Foundayo, and compounded semaglutide. The right choice depends on whether you want a brand-name FDA-approved product, an oral pill instead of an injection, or the lowest possible price — and on what your clinician recommends for your situation.

Prices in this article reflect publicly reported figures as of May 2026 and change frequently. Confirm any price directly with the manufacturer, pharmacy or program before making a decision.